Technological Offers
DIABET1: Biomarkers for early diagnosis of diabetes 1
Description
Method for early diagnosis (prior to disease debut) of DT1, based on the mRNA expression level of two new markers.
The analysis is performed on a blood sample in which circulating lymphocytes are isolated. The method allows the results to be obtained quickly and affordably by quantitative PCR, a technique widely used in the health sector.
Medical need
Diabetes mellitus type 1 (DM1) is an autoimmune disease with no cure that leads to a progressive destruction of insulin-producing beta cells.
The evolution is progressive and goes through three stages:
- Appearance of antibodies, without insulinitis or disease.
- Onset of insulinitis, without hyper- or hypoglycemia.
- Debut of the disease, at this point the rate of beta cells is very low.
Results
A study was performed in 10 healthy patients and 18 patients with debuting DT1.
CD4+ T lymphocytes were isolated from peripheral blood and the expression of three cannabinoid receptors was analyzed by PCR.
Two of the receptors showed significant differences in their expression in patients with recent debut with respect to controls.
Prevalence |
Market |
Other solutions |
Worldwide: 8.4M people. Europe: 1M people. Spain: 150K people. An increase is expected in the coming years. |
The DT1 market size is estimated at $15.95 billion in 2024, and is expected to reach $24.36 billion in 2031, with a CARG of 6.2% | Currently, stage 1 detection is performed by blood antibody testing. These antibodies are detectable in only 70% of cases. |
Diagnosis
IBIMA Plataforma BIONAND inventors
SILVANA YANINA ROMERO ZERBO
Research group of IBIMA involved: A-01
MARÍA SOLEDAD RUIZ DE ADANA NAVAS
Research group of IBIMA involved: A-01
RAJAA EL BEKAY RIZKY
Research group of IBIMA involved: A-01
GABRIEL OLVEIRA FUSTER
Research group of IBIMA involved: A-01
GEMMA ROJO MARTÍNEZ
Research group of IBIMA involved: A-01